This article is more than 5 years old. Information may no longer be current.
VIDEO: Precision medicine, immunotherapy show promise in neuro-oncology research
Click Here to Manage Email Alerts
CHICAGO — Andrew B. Lassman, MD, discusses advances made within two major themes — precision medicine and immunotherapy — for the treatment of primary brain tumors at the ASCO Annual Meeting.
Lassman, chief of neuro-oncology at Columbia University Medical Center and medical director for the clinical protocol in the data management office of the Herbert Irving Comprehensive Cancer Center at NewYork–Presbyterian Hospital, also noted the importance of several ongoing studies designed to evaluate the treatment of brain metastases.
“We continue to push forward the frontier to try to improve outcomes for patients, and we look forward to future discoveries,” he said. – by Kristie L. Kahl
Disclosure: Lassman reports honoraria from Prime Oncology; consultant fees from Abbvie, AstraZeneca, BioClinica, Cortice Biosciences, Genentech/Roche, Novartis, Novocure, Oxigene, Regeneron, Sapience and VBI Vaccines and research funding from Abbvie, Aeterna Zentaris, Agenus, Amgen, Bayer/Onyx, Boehringer Ingelheim, Bristol-Myers Squibb, Celldex, e-Therapeutics, Genentech/Roche, GlaxoSmithKline, ImmunoCellular Therapeutics, Kadmon, Karyopharm Therapeutics, MedImmune, Merck, Millennium, Northwest Biotherapeutics, Novartis, Novocure, Novocure, Pfizer, Plexxikon, Regeneron, Stemline Therapeutics, Tocagen and VBL Therapeutics.